Nalls Sherbakoff Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nalls Sherbakoff Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.6K	Hold	250	–	–	0.03%	207
2026 Q1	$31.9K	Sell	250 -100	-29%	-$12.5K	0.02%	234
2025 Q4	$42.7K	Hold	350	–	–	0.03%	217
2025 Q3	$35.1K	Hold	350	–	–	0.02%	237
2025 Q2	$29K	Buy	350 +100	+40%	+$7.98K	0.02%	250
2025 Q1	$20.3K	Buy	+250	New	+$22.3K	0.02%	247
2023 Q4	$28.3K	Buy	317 +67	+27%	+$4.98K	0.03%	210
2023 Q3	$18.3K	Hold	250	–	–	0.02%	228
2023 Q2	$21K	Hold	250	–	–	0.02%	223
2023 Q1	$18.7K	Buy	+250	New	+$20.7K	0.02%	235
2018 Q4	$18K	Buy	+250	New	+$20.1K	0.03%	223

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Nalls Sherbakoff Group's XBI Position: Q2 2026 in Review

Nalls Sherbakoff Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 250 shares worth $39.6K. The position accounts for 0.03% of the portfolio, ranked #207.

Nalls Sherbakoff Group first reported a position in XBI in Q4 2018 and has held it in 11 quarters since. The position peaked at $42.7K in Q4 2025. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Nalls Sherbakoff Group held 250 shares of State Street SPDR S&P Biotech ETF worth $39.6K as of Q2 2026.
Nalls Sherbakoff Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.03% of Nalls Sherbakoff Group's portfolio in Q2 2026, its #207 holding.
Nalls Sherbakoff Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and has held it in 11 quarters since.
Nalls Sherbakoff Group's State Street SPDR S&P Biotech ETF position peaked at $42.7K in Q4 2025.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Nalls Sherbakoff Group's 13F filing for Q2 2026, filed 17 Aug 2026.